HK Stock MarketDetailed Quotes

BEONE MEDICINES (06160)

Watchlist
  • 190.500
  • +5.600+3.03%
Market Closed Apr 15 16:07 CST
293.64BMarket Cap131.47P/E (TTM)

About BEONE MEDICINES Company

The company is a limited liability company incorporated in the Cayman Islands, established on October 28, 2010. It was listed and began trading on the Nasdaq Stock Market in the United States on February 8, 2016, on the Hong Kong Stock Exchange on August 8, 2018, and on the Shanghai Stock Exchange on December 15, 2021. The company focuses on the research, development, production, and commercialization of innovative pharmaceuticals. Its main products include Brukinsa (zanubrutinib), Baizean (tislelizumab), Baihuize (pamiparib), Baiyueda (sotirio), Antaisi (talazoparib), Angawei (denosumab), Beilituo (bevacizumab), Kailuos (carfilzomib), Baihe'an (zenidatuzumab), Sawenke (sotorasib), Kaizebai (daratumumab), Pubeixi (Avastin biosimilar), Baituowei (goserelin microspheres for injection), Taifeile (dabrafenib), Majijing (trametinib), Weiquant (pazopanib), Feinituo (everolimus), Zankeda (ceritinib), and others.

Company Profile

Symbol06160
Company NameBEONE MEDICINES
ISINCH1391448177
Listing DateAug 8, 2018
Issue Price108.00
Shares Offered65.60M share(s)
FoundedJun 28, 2018
Registered AddressSwitzerland
Chairmanleiqiang ou
Secretaryqingling zhou
Audit InstitutionErnst & Young, Ernst & Young Huaming Certified Public Accountants (Special General Partnership), Ernst & Young LLP, Ernst & Young AG
Company CategoryOverseas registration of Mainland Individuals control
Registered Officec/o BeOne Medicines I GmbH, Aeschengraben 27, 4051 Basel, Switzerland
Head Office and Principal Place of BusinessRoom 1901, 19th Floor, Phase 1, Lee Gardens, 33 Hysan Road, Causeway Bay, Hong Kong
Fiscal Year Ends12-31
Employees12000
MarketHong Kong motherboard
Phone4008623235
Fax010-85148699
Emailir@beonemed.com
Websitehttps://www.beonemedicines.com
BusinessBeiGene is a global, commercial-stage biotechnology company focused on the research, development, manufacturing, and commercialization of innovative medicines.

Company Executives

  • Name
  • Position
  • Salary
  • leiqiang ou
  • Chairman, Chief Executive Officer, Executive Director, Authorized Representative
  • --
  • xiaodong wang
  • Non-executive Director
  • --
  • Olivier Brandicourt
  • Independent Non-Executive Director, Audit Committee Members
  • 527.00K
  • Margaret Han Dugan
  • Independent Non-Executive Director, Chair of the Compensation Committee, Member of the Commercial and Medical Affairs Advisory Committee
  • 549.00K
  • Michael Goller
  • Independent Non-Executive Director, Nomination and Corporate Governance Committee Members
  • 519.00K
  • Anthony C. Hooper
  • Independent Non-Executive Director, Chair of the Nomination Committee, Audit Committee Members
  • 557.00K
  • Ranjeev Krishana
  • Independent Non-Executive Director, Members of the Compensation Committee
  • 524.00K
  • Alessandro Riva
  • Independent Non-Executive Director, Nomination Committee Members
  • 529.00K
  • Corazon (Corsee) D. Sanders
  • Independent Non-Executive Director, Audit Committee Members
  • --
  • Shalini Sharp
  • Independent Non-Executive Director, Chair of the Audit Committee, Nomination Committee Members
  • 533.00K
  • qingqing yi
  • Independent Non-Executive Director, Members of the Compensation Committee
  • 524.00K
  • xiaobin wu
  • President, General Manager, Chief Operating Officer
  • --
  • Aaron Rosenberg
  • Chief Financial Officer
  • --
  • lai wang
  • Global Head of R&D
  • --
  • Chan Lee
  • Senior Vice President, General Counsel
  • --
  • qingling zhou
  • Authorized Representative, Company Secretary
  • --
Market Insights
Petroleum
No. Symbol 20D % Chg
Sample Name
Sample Code
 -0.84%
Sample Name
Sample Code
 -6.10%
Sample Name
Sample Code
 -6.20%
4
SHANGHAI PECHEM
00338
-10.56%
5
YANCHANG PETRO
00346
-11.83%
View More
No. Symbol 20D % Chg
Sample Name
Sample Code
 +23.12%
Sample Name
Sample Code
 +22.06%
Sample Name
Sample Code
 +16.30%
4
Hangzhou Shunwang Technology
300113
+12.45%
5
Ucloud Technology Co., Ltd
688158
+9.55%
View More
China and the US begin implementing the Kuala Lumpur economic and trade consultation consensus.
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"

- No more -